Aether Therapeutics
Austin, US · Delaware corporation
Aether Therapeutics is a clinical-stage biotech company developing ATX-1209 (oral 6β-naltrexol), a first-in-class µ-opioid receptor modulator designed to reduce opioid-induced physical dependence without affecting pain relief or triggering withdrawal. Its pipeline targets chronic opioid pain dependence, opioid use disorder, neonatal opioid withdrawal syndrome, and acute/cancer pain.
Founders & leadership
JD
John D HarrisNamed on SEC filing
EK
Eric K OlsonNamed on SEC filing
WS
Wolfgang SadeeinNamed on SEC filing
JS
Jon S SaxeNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$4.1M disclosed across 1 round · 2024
▶$4.1MraisedJan 2024 · 1 investors · BiotechnologyRule 506(b)
▶$4.1MraisedJan 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John D HarrisExecutive Officer, Director
- Eric K OlsonDirector
- Wolfgang SadeeDirector
- Jon S SaxeExecutive Officer, Director
- Offering amount
- $6.6M
- Amount sold
- $4.1M
- Minimum investment
- $50K
- Proceeds to insiders
- $150K
- Placement agents
- Issuer Direct Sales Only
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAltaThera Pharmaceuticals5 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
ADvantage Therapeutics4 shared keywords
Areteia Therapeutics4 shared keywordsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
Aera Therapeutics4 shared keywordsAera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases. The company focuses on advancing transformative treatments in areas including oncology, rare genetic diseases, and cell therapies.
Companies competing with Aether Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Aether Therapeutics do?
- Aether Therapeutics is a clinical-stage biotech company developing ATX-1209 (oral 6β-naltrexol), a first-in-class µ-opioid receptor modulator designed to reduce opioid-induced physical dependence without affecting pain relief or triggering withdrawal. Its pipeline targets chronic opioid pain dependence, opioid use disorder, neonatal opioid withdrawal syndrome, and acute/cancer pain.
- How much funding has Aether Therapeutics raised?
- Aether Therapeutics has disclosed $4.1M raised across 1 round.
- Where is Aether Therapeutics headquartered?
- Aether Therapeutics is headquartered in Austin, US.